{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:18:39Z","timestamp":1771885119603,"version":"3.50.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113916","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T02:50:13Z","timestamp":1634007013000},"page":"113916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors"],"prefix":"10.1016","volume":"227","author":[{"given":"Soo-Yeon","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarajana","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seojeong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesh","family":"Bist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surendra","family":"Kunwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-436X","authenticated-orcid":false,"given":"Tara Man","family":"Kadayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haejin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naeun","family":"Sheen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seojeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Hwa","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eung-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6256-3042","authenticated-orcid":false,"given":"Youngjoo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113916_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA","volume":"68","author":"Bray","year":"2018","journal-title":"Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2021.113916_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrm.2017.43","article-title":"Physiological functions of programmed DNA breaks in signal-induced transcription","volume":"18","author":"Puc","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2021.113916_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q.\u00a0Rev. Biophys."},{"key":"10.1016\/j.ejmech.2021.113916_bib5","first-page":"338","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib6","first-page":"1504","article-title":"Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints","volume":"24","author":"DArcy","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/cb300648v","article-title":"Drugging topoisomerases: lessons and challenges","volume":"8","author":"Pommier","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib8","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1021\/bi1009419","article-title":"A\u00a0novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2\/M phase cell cycle arrest to K562 cells","volume":"49","author":"Wu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113916_bib9","doi-asserted-by":"crossref","first-page":"11848","DOI":"10.1158\/0008-5472.CAN-07-1615","article-title":"Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death","volume":"67","author":"Ganguly","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ejmech.2015.07.007","article-title":"An, Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors","volume":"101","author":"Yu","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib11","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/acs.jafc.7b01762","volume":"65","author":"Qin","year":"2017","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/14756366.2018.1516651","article-title":"The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor","volume":"34","author":"Yu","year":"2019","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/B978-0-12-812522-9.00005-1","article-title":"Inhibitors and poisons of mammalian type II topoisomerases","volume":"11","author":"Murphy","year":"2017","journal-title":"Adv. Mol. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113916_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.113916_bib15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/0022-2836(92)90863-F","article-title":"Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events","volume":"228","author":"S\u00f8rensen","year":"1992","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib16","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1073\/pnas.89.7.3025","article-title":"Suramin is an inhibitor of DNA topoisomerase II in\u00a0vitro and in Chinese hamster fibrosarcoma cells","volume":"89","author":"Bojanowski","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113916_bib17","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1021\/bi952888n","article-title":"The interaction of coumarin antibiotics with fragments of DNA gyrase B protein","volume":"35","author":"Gormley","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113916_bib18","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1074\/jbc.271.4.2313","article-title":"Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin","volume":"271","author":"Sekiguchi","year":"1996","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib19","doi-asserted-by":"crossref","first-page":"17643","DOI":"10.1074\/jbc.273.28.17643","article-title":"Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage","volume":"273","author":"Fortune","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib20","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1073\/pnas.91.5.1781","article-title":"Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp","volume":"91","author":"Roca","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113916_bib21","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1021\/bi00061a033","article-title":"The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs","volume":"32","author":"Ali","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113916_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A\u00a0new-class Antibacterial-almost. Lessons in drug discovery and development: a critical analysis of more than 50 Years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2021.113916_bib23","first-page":"535","article-title":"Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I","volume":"9","author":"Bridewell","year":"1997","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2165\/00003495-200565070-00008","article-title":"Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy","volume":"65","author":"Cvetkovi\u0107","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2021.113916_bib25","first-page":"1790","article-title":"Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells","volume":"7","author":"Benini","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib26","first-page":"6145","article-title":"Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases","volume":"61","author":"Song","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0022-3565(24)29247-8","article-title":"Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors","volume":"299","author":"Zhang","year":"2001","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.113916_bib28","first-page":"402","article-title":"A\u00a0phase I and pharmacologic study of suramin with sequential adriamycin in patients with advanced solid tumors","author":"Qu","year":"2002","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib29","first-page":"5663","article-title":"Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells","volume":"53","author":"Ali-Osman","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib30","first-page":"5487","article-title":"Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin","volume":"53","author":"Rappa","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib31","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.2174\/092986710793361252","article-title":"Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs","volume":"17","author":"Salerno","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Skok","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib33","doi-asserted-by":"crossref","first-page":"105594","DOI":"10.1016\/j.ejps.2020.105594","article-title":"Multiple topoisomerase I (TopoI), topoisomerase II (TopoII) and tyrosyl-DNA phosphodiesterase (TDP) inhibitors in the development of anticancer drugs","volume":"156","author":"Baglini","year":"2021","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.113916_bib34","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.2174\/0929867325666180607094856","article-title":"Dual inhibitors as a new challenge for cancer multidrug resistance treatment","volume":"26","author":"Stankovi\u0107","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/1568026619666190401113350","article-title":"Recent advances in use of topoisomerase inhibitors in combination cancer therapy","volume":"19","author":"Wang","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","article-title":"A\u00a0comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade","volume":"171","author":"Liang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib37","doi-asserted-by":"crossref","first-page":"15580","DOI":"10.1021\/bi991792g","article-title":"DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition","volume":"38","author":"Fortune","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113916_bib38","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1158\/0008-5472.CAN-07-0804","article-title":"Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone gamma-H2AX as a biomarker of DNA damage","volume":"67","author":"Rao","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bcp.2018.05.006","article-title":"New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I\/II but reveal different p53-dependency in inducing G2\/M arrest and apoptosis","volume":"154","author":"Tian","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113916_bib40","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/jm970044r","article-title":"Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors","volume":"40","author":"Deady","year":"1997","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1021\/jm501023q","article-title":"A\u00a0series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases","volume":"58","author":"Kwon","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib42","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1016\/j.bmc.2015.04.031","article-title":"Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines","volume":"23","author":"Kadayat","year":"2015","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib43","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1021\/acs.jmedchem.9b00970","article-title":"Discovery and biological evaluations of halogenated 2,4-diphenyl indeno[1,2-b]pyridinol derivatives as potent topoisomerase II\u03b1-targeted chemotherapeutic agents for breast cancer","volume":"62","author":"Kadayat","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib44","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1016\/j.bmcl.2017.06.025","article-title":"2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: the role of the chlorine substituent, Biorg","volume":"27","author":"Thapa Magar","year":"2017","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113916_bib45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ejmech.2017.01.003","article-title":"Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: non-intercalative catalytic topoisomerase I and II dual inhibitor","volume":"127","author":"Park","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/138945010790711996","article-title":"Halogen atoms in the modern medicinal chemistry: hints for the drug design","volume":"11","author":"Hernandes","year":"2010","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2021.113916_bib47","doi-asserted-by":"crossref","first-page":"6652","DOI":"10.1021\/ja00309a038","article-title":"The role of the chlorine substituents in the antibiotic vancomycin: preparation and characterization of mono-and didechlorovancomycin","volume":"107","author":"Harris","year":"1985","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113916_bib48","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib49","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1021\/acs.jmedchem.7b01788","article-title":"Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design","volume":"61","author":"Meanwell","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib50","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1039\/C7CC02372C","article-title":"A\u00a0novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase II\u03b1 catalytic inhibitor, for caspase 3-independent anticancer activity","volume":"53","author":"Jeon","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.113916_bib51","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.bmc.2018.09.021","article-title":"A\u00a0new phenolic series of indenopyridinone as topoisomerase inhibitors: design, synthesis, and structure-activity relationships","volume":"26","author":"Shrestha","year":"2018","journal-title":"Biorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib52","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2015.07.002","article-title":"Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: synthesis, anticancer activity, and structure-activity relationship study","volume":"62","author":"Kadayat","year":"2015","journal-title":"Biorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib53","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.tetlet.2006.12.102","article-title":"An efficient and expeditious microwave-assisted synthesis of 4-azafluorenones via a multi-component reaction","volume":"48","author":"Tu","year":"2007","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2021.113916_bib54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ejmech.2017.06.018","article-title":"Discovery and structure-activity relationship studies of 2-benzylidene-2, 3-dihydro-1H-inden-1-one and benzofuran-3 (2H)-one derivatives as a novel class of potential therapeutics for inflammatory bowel disease","volume":"137","author":"Kadayat","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib55","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1158\/1535-7163.MCT-09-0016","article-title":"Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity","volume":"8","author":"Pfister","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2021.113916_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050494","article-title":"Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues","volume":"7","author":"Pfister","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113916_bib57","first-page":"2735","article-title":"The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule","volume":"16","author":"Ishida","year":"1996","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00001813-199607000-00011","article-title":"The effect of dexrazoxane (ICRF-187) on doxorubicin-and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells","volume":"7","author":"Hasinoff","year":"1996","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.ejmech.2021.113916_bib59","first-page":"4295","article-title":"MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy","volume":"5","author":"Yoshida","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s002800050805","article-title":"MST-16, a novel derivative of bis (2, 6-dioxopiperazine), synergistically enhances the antitumor effects of anthracyclines","volume":"42","author":"Inutsuka","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113916_bib61","first-page":"595","article-title":"Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents","volume":"49","author":"Eder","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib62","first-page":"1367","article-title":"Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide","volume":"4","author":"Holm","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib63","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-04-2343","article-title":"Dexrazoxane protects against myelosuppression from the DNA cleavage\u2013enhancing drugs etoposide and daunorubicin but not doxorubicin","volume":"11","author":"Hofland","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib64","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00280-009-0934-8","article-title":"Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane","volume":"64","author":"Attia","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113916_bib65","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/mutage\/ger013","article-title":"Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells","volume":"26","author":"Bakheet","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1016\/j.ejmech.2021.113916_bib66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.113916_bib67","first-page":"10","article-title":"Type II DNA topoisomerases cause spontaneous double-strand breaks in genomic DNA","author":"Morimoto","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2021.113916_bib68","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib69","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.2011.498","article-title":"Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets","volume":"106","author":"Gilbert","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113916_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/genes10100791","article-title":"Broken by the cut: a journey into the role of topoisomerase II in DNA fragility","volume":"10","author":"Atkin","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.ejmech.2021.113916_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2141.2000.01843.x","article-title":"Topoisomerase II inhibitor-related acute myeloid leukaemia","volume":"109","author":"Pui","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2021.113916_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cancergencyto.2005.08.006","article-title":"Genotoxicity of etoposide: greater susceptibility of MLL than other target genes","volume":"164","author":"Ng","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.ejmech.2021.113916_bib73","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1634\/stemcells.2005-0227","article-title":"Stringent regulation of DNA repair during human hematopoietic differentiation: a gene expression and functional analysis","volume":"24","author":"Bracker","year":"2006","journal-title":"Stem Cell."},{"key":"10.1016\/j.ejmech.2021.113916_bib74","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.stem.2010.05.016","article-title":"A\u00a0distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal","volume":"7","author":"Milyavsky","year":"2010","journal-title":"Cell Stem cell"},{"key":"10.1016\/j.ejmech.2021.113916_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/2472555218777968","article-title":"A\u00a0multiplexed screening assay to evaluate chemotherapy-induced myelosuppression using healthy peripheral blood and bone marrow","volume":"23","author":"Javarappa","year":"2018","journal-title":"SLAS discovery : advancing life sciences R & D"},{"key":"10.1016\/j.ejmech.2021.113916_bib76","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0167-4781(98)00128-6","article-title":"Investigating the biological functions of DNA topoisomerases in eukaryotic cells","volume":"1400","author":"Nitiss","year":"1998","journal-title":"Biochim. Biophys. Acta Gene Struct. Expr."},{"key":"10.1016\/j.ejmech.2021.113916_bib78","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2021.113916_bib79","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/nar\/gkn937","article-title":"The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing","volume":"37","author":"Deweese","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113916_bib80","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1568026033452519","article-title":"Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes","volume":"3","author":"Wilstermann","year":"2003","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib81","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1021\/tx500245m","article-title":"HU-331 is a catalytic inhibitor of topoisomerase II\u03b1","volume":"27","author":"Regal","year":"2014","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113916_bib82","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1038\/s41467-020-16926-x","article-title":"DNA double-strand breaks induce H2Ax phosphorylation domains in a contact-dependent manner","volume":"11","author":"Collins","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.113916_bib83","first-page":"5","article-title":"Double strand break repair functions of histone H2AX","volume":"750","author":"Scully","year":"2013","journal-title":"Curr. Res. Struct. Biol."},{"key":"10.1016\/j.ejmech.2021.113916_bib84","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.taap.2018.07.007","article-title":"Monoubiquitinated \u03b3-H2AX: abundant product and specific biomarker for non-apoptotic DNA double-strand breaks","volume":"355","author":"Luczak","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113916_bib85","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejmech.2017.03.048","article-title":"Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: topoisomerase I and II\u03b1 dual inhibitors with DNA non-intercalative catalytic activity","volume":"133","author":"Bist","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113916_bib86","doi-asserted-by":"crossref","first-page":"12857","DOI":"10.1039\/C9CC05524J","article-title":"A\u00a0chromenone analog as an ATP-competitive, DNA non-intercalative topoisomerase II catalytic inhibitor with preferences toward the alpha isoform","volume":"55","author":"Park","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2021.113916_bib87","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/ci050357s","article-title":"Molecular field extrema as descriptors of biological activity: definition and validation","volume":"46","author":"Cheeseright","year":"2006","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113916_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061540","article-title":"Specific roles of HSP27 S15 phosphorylation augmenting the nuclear function of HER2 to promote trastuzumab resistance","volume":"12","author":"Hwang","year":"2020","journal-title":"Cancers"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:33:00Z","timestamp":1759329180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":88,"alternative-id":["S0223523421007650"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113916","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113916"}}